MetaCap

QuidelOrtho Corporation (QDEL)

NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

8.32-0.60 (-6.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QDEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$570.86M
EPS (TTM)
-$5.39
52-week range
8.06 – 35.58
Day range
8.06 – 8.95
Volume / Avg
2.61M / 2.04M
Beta
—

52-week range

$8.06$35.58

QDEL stock today

On Nov 20, QDEL ended the session at $8.32, shedding $0.60 (6.73%), versus the S&P 500's 3.70% decline. At this level, QDEL sits near the bottom of its 52-week range of $8.06 to $35.58: 76.6% below the high, set on Jan 16, 2026 and 3.2% above the low. QDEL is down 70.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.8%.

QuidelOrtho has posted a net loss over the last twelve months (EPS of -$5.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About QuidelOrtho

Company profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Brian J. Blaser
Headquarters
San Diego, CA
Employees
6,500

Financial highlights

Full financials

In fiscal 2025, QuidelOrtho generated $2.73 billion in revenue, down 1.9% from fiscal 2024, its first annual decline since 2024. QuidelOrtho reported a net loss of $1.13 billion, compared with a loss of $2.05 billion a year earlier. Gross margin was 46.7% (up from 46.2%) and operating margin -33.7%.

QuidelOrtho annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2022
Revenue$2.73B$2.78B$3.00B$3.27B$1.70B
Growth-1.89%-7.17%-8.21%+92.28%+2.22%
Net income$-1.13B$-2.05B$-10.10M$548.70M$704.20M
EPS (diluted)$-16.69$-30.54$-0.15$9.56$16.43

Analyst forecast

Forecast

Consensus (3 analysts)

hold

Avg. price target

$15.00+80.29%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $12.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.80 vs $0.18
Surprise
+344.44%

QDEL news

All QDEL news

QuidelOrtho peers

Health Care sector
QDEL peer companies
CompanyPrice% ChgMarket capCompare
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs QDEL
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs QDEL
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs QDEL
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs QDEL
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs QDEL
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs QDEL
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs QDEL
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs QDEL

Indexes, lists and sector

QuidelOrtho stock FAQ

What is QuidelOrtho's stock price today?

QDEL last traded at $8.32 as of Nov 20, 4:00 PM EST, down 6.73% on the day. Prices are delayed at least 15 minutes.

Who is QuidelOrtho's CEO?

Mr. Brian J. Blaser is the chief executive officer of QuidelOrtho Corporation, which has about 6,500 employees.

What is the QDEL 52-week high?

The 52-week high for QDEL is $35.58 and the 52-week low is $8.06. The stock is currently 76.6% below its high.

Compare QDEL